This correction is made in compliance with Section 39n(3) of the Act and becomes effective on the day it is published on the official notice board. The List’s correction lays down the full list of medicinal products (MPs) and foods for special medicinal purposes (FSMPs) reimbursed from the public health insurance system subject to the Institute’s decision, including their maximum or announced ex-factory prices, the amount and the terms of reimbursement, incl. their highest possible reimbursement for the end consumer, along with the amount of the extra payment in the eligible limit. In addition, the List contains the basic reimbursements of reference groups and explains the reasoning behind the basic reimbursements, along with a full list of the medicinal products and foods for special medicinal purposes included in the reference groups.
In the published correction, the Institute added valid temporary reimbursement price and conditions of reimbursement of the pharmaceutical Inlyta (codes 0193517 a 0193520), in the therapy of renal carcinoma in patients previously treated with sunitinib.
List of prices of medicinal products and fedical purposes
- Legend for the List of PandR MPs and FSMPs.pdf, soubor typu pdf, (1.48 MB)
- Legend for the List of PandR MPs and FSMPs used in institutional care only.pdf, soubor typu pdf, (1.44 MB)